EUVIMEDEUVIMED entdecken
Crossref

Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022

Tanya R Diefenbach-Elstob, Presa Chanthalavanh, Monica E Bobbitt, Sook Kwan Brown, Cleve Rynehart, Natalie Spirason, Heidi Peck, Yi-Mo Deng, Clyde Dapat, Kanta Subbarao, Ian G Barr

Communicable Diseases Intelligence · 2023

DOI: 10.33321/cdi.2023.47.43 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2023. Verfasst von Tanya R Diefenbach-Elstob und 10 weiteren Autor:innen. Beteiligte Einrichtung: WHO Collaborating Centre for Reference and Research on Influenza . Tanya.DiefenbachElstob@Influenzacentre.org. Hauptthemen laut MEDLINE: Influenza A virus, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As part of its role in the World Health Organization’s (WHO) Global Influenza Surveillance and Response System (GISRS), the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne received a record total of 12,073 human influenza positive samples during 2022. Viruses were analysed for their antigenic, genetic and antiviral susceptibility properties. Selected viruses were propagated in qualified cells or embryonated hen’s eggs for potential use in seasonal influenza virus vaccines. In 2022, influenza A(H3N2) viruses predominated over influenza A(H1N1)pdm09 and B viruses, accounting for 77% of all viruses analysed. The majority of A(H1N1)pdm09, A(H3N2) and influenza B viruses analysed at the Centre were found to be antigenically and genetically similar to the respective WHO recommended vaccine strains for the southern hemisphere in 2022. Of 3,372 samples tested for susceptibility to the neuraminidase inhibitors oseltamivir and zanamivir, two A(H1N1)pdm09 viruses showed highly reduced inhibition against oseltamivir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza A virusInfluenza VaccinesInfluenza, HumanAnimalsFemaleHumansAustraliaChickensDrug Resistance, ViralInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeOseltamivirWorld Health OrganizationZanamivirAntiviral Agents

Stichwörter der Autor:innen

influenzavaccineGISRSsurveillancelaboratoryannual reportWHO

Substanzen

Influenza VaccinesOseltamivirZanamivirAntiviral Agents

Autor:innen und Institutionen

  • WHO Collaborating Centre for Reference and Research on Influenza . Tanya.DiefenbachElstob@Influenzacentre.org.
  • WHO Collaborating Centre for Reference and Research on Influenza.

Zitieren

APA

Diefenbach-Elstob, T. R., Chanthalavanh, P., Bobbitt, M. E., Brown, S. K., Rynehart, C., Spirason, N., Peck, H., Deng, Y. M., Dapat, C., Subbarao, K., & Barr, I. G. (2023). Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2023.47.43

Vancouver

Diefenbach-Elstob TR, Chanthalavanh P, Bobbitt ME, Brown SK, Rynehart C, Spirason N, et al. Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022. Communicable Diseases Intelligence. 2023. doi:10.33321/cdi.2023.47.43

BibTeX
@article{DiefenbachElstob2023,
  author = {Diefenbach-Elstob, Tanya R and Chanthalavanh, Presa and Bobbitt, Monica E and Brown, Sook Kwan and Rynehart, Cleve and Spirason, Natalie and Peck, Heidi and Deng, Yi-Mo and Dapat, Clyde and Subbarao, Kanta and Barr, Ian G},
  title = {Report on influenza viruses received and tested by the Melbourne WHO Collaborating Centre for Reference and Research on Influenza during 2022},
  journal = {Communicable Diseases Intelligence},
  year = {2023},
  doi = {10.33321/cdi.2023.47.43}
}
Kostenlos starten →